Loading
Measuring the proteins in a tumour, which is what drugs actually hit, rather than the genes that encode them.
Proteomics measures the proteins and phosphorylation sites in a tumour directly, using liquid chromatography tandem mass spectrometry with isobaric labelling to quantify thousands of proteins and phosphosites at once. Mass-spectrometry proteomics (CPTAC) reveals pathway activity and ADC target abundance that transcript levels do not predict, since RNA and protein levels often disagree. Quantitative IHC and mass-spec assays of HER2 and TROP2 aim to improve ADC patient selection by measuring the actual antigen the drug binds rather than a proxy. Throughput and standardisation remain the barriers to routine clinical use, and it is still open whether protein-level selection will outperform established IHC scoring in trials. For a newcomer, proteomics measures what drugs actually hit, the proteins, rather than the genes that encode them.
Liquid chromatography tandem mass spectrometry with isobaric labelling quantifies proteins and phosphosites.
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
Fixes the window in which a blood test could plausibly work and shows why CA 19-9 alone is not enough: half of early cases are missed even at diagnosis, and Lewis-negative patients are missed entirely.
The proof of principle for multi-cancer blood tests that include pancreas; the sensitivity figures come from known cancers, not from screening.
It quantifies how little DNA an operable pancreatic cancer sheds and why every serious early detection panel pairs DNA with proteins.
It is the reference multi-platform dataset and the reason a KRAS wild-type report is treated as a search for another driver rather than as an absence.
Query for this technology: (TITLE:"proteomics" OR ABSTRACT:"proteomics" OR TITLE:"proteogenomic" OR ABSTRACT:"proteogenomic" OR TITLE:"phosphoproteomics" OR ABSTRACT:"phosphoproteomics") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Proteomics & phosphoproteomics, not a curated reading list.
Shares Elucidate Bio, Find the parts of a tumour the drug never reaches, A global rapid tissue donation network for metastatic disease, Spatial-omics-guided treatment selection.
Shares Reverse-phase protein array (RPPA), A global rapid tissue donation network for metastatic disease, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
Shares Find E3 ligases that only tumours have, and build degraders around them, An open map of which cancer proteins any drug can stick to, Screen glue-like compounds against every cancer cell line and publish it.
Shares Nonagen Bioscience, OncoHost, Acrivon Therapeutics, A commons for leftover trial biospecimens with standard access for approved research.
Shares Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers, Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium, Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection, Pancreatic ductal adenocarcinoma.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
A Python package that streams CPTAC proteogenomic cancer datasets into pandas.